Measurement properties of the 12-item Short Form Health Survey version 2 in Australians with lung cancer: a Rasch analysis.
Health status
Lung cancer
Psychometrics
Rasch analysis
Journal
Health and quality of life outcomes
ISSN: 1477-7525
Titre abrégé: Health Qual Life Outcomes
Pays: England
ID NLM: 101153626
Informations de publication
Date de publication:
31 May 2021
31 May 2021
Historique:
received:
10
10
2019
accepted:
21
05
2021
entrez:
1
6
2021
pubmed:
2
6
2021
medline:
11
6
2021
Statut:
epublish
Résumé
The 12-item Short-Form Health Survey version 2 (SF-12v2), a widely used, generic patient-reported measure of health status that provides summary scores of physical and mental health. No study to date has examined the measurement properties of the SF-12v2 in patients with lung cancer using Rasch analysis. The aim of this study was to extend the psychometric evaluations of the SF-12 within the lung cancer population to ensure its validity and reliability to assess the health status in this population. Participants in the Victorian Lung Cancer Registry (VLCR) who completed the SF-12v2 between 2012 and 2016 were included in this study. The structural validity of the SF-12v2 was assessed using Rasch analysis. Overall fit to the Rasch measurement model was examined as well as five key measurement properties: uni-dimensionality, response thresholds, internal consistency, measurement invariance and targeting. A total of 342 participants completed the SF-12v2 three months following their lung cancer diagnosis. The SF-12 Physical Component Score (PCS-12) did not fit the overall Rasch measurement model (χ Rasch analysis suggests that there is general support for the reliability of the SF-12v2 as a measure of physical and mental health in people with lung cancer. However, the appropriateness of some items (e.g. pain) in the PCS-12 is questionable and further refinement of the scale including changing the response options may be required to improve the ability of the SF-12v2 to more appropriately assess the health status of this population.
Sections du résumé
BACKGROUND
BACKGROUND
The 12-item Short-Form Health Survey version 2 (SF-12v2), a widely used, generic patient-reported measure of health status that provides summary scores of physical and mental health. No study to date has examined the measurement properties of the SF-12v2 in patients with lung cancer using Rasch analysis. The aim of this study was to extend the psychometric evaluations of the SF-12 within the lung cancer population to ensure its validity and reliability to assess the health status in this population.
METHODS
METHODS
Participants in the Victorian Lung Cancer Registry (VLCR) who completed the SF-12v2 between 2012 and 2016 were included in this study. The structural validity of the SF-12v2 was assessed using Rasch analysis. Overall fit to the Rasch measurement model was examined as well as five key measurement properties: uni-dimensionality, response thresholds, internal consistency, measurement invariance and targeting.
RESULTS
RESULTS
A total of 342 participants completed the SF-12v2 three months following their lung cancer diagnosis. The SF-12 Physical Component Score (PCS-12) did not fit the overall Rasch measurement model (χ
CONCLUSIONS
CONCLUSIONS
Rasch analysis suggests that there is general support for the reliability of the SF-12v2 as a measure of physical and mental health in people with lung cancer. However, the appropriateness of some items (e.g. pain) in the PCS-12 is questionable and further refinement of the scale including changing the response options may be required to improve the ability of the SF-12v2 to more appropriately assess the health status of this population.
Identifiants
pubmed: 34059079
doi: 10.1186/s12955-021-01794-w
pii: 10.1186/s12955-021-01794-w
pmc: PMC8165769
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
157Références
Int J Rehabil Res. 1997 Mar;20(1):71-80
pubmed: 9089016
Med Care. 1996 Mar;34(3):220-33
pubmed: 8628042
J Arthroplasty. 2017 Feb;32(2):351-354
pubmed: 27665243
Int J Nurs Stud. 2009 Mar;46(3):380-93
pubmed: 19059593
J Clin Epidemiol. 1998 Nov;51(11):1171-8
pubmed: 9817135
Eur J Cancer. 1994;30A(5):635-42
pubmed: 8080679
J Voice. 2010 Mar;24(2):193-8
pubmed: 19185454
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Value Health. 2004 Sep-Oct;7 Suppl 1:S22-6
pubmed: 15367240
J Physiother. 2017 Jan;63(1):1-3
pubmed: 27988245
Intern Med J. 2017 Dec;47(12):1454-1457
pubmed: 29224197
J Neurosci Nurs. 2014 Feb;46(1):34-45
pubmed: 24399165
Arthritis Rheum. 2007 Dec 15;57(8):1358-62
pubmed: 18050173
Qual Life Res. 2010 Mar;19(2):231-41
pubmed: 20094805
Prev Med. 2017 Jun;99:164-170
pubmed: 28219783
PLoS One. 2013 Apr 12;8(4):e61191
pubmed: 23593428
Qual Life Res. 2020 Jan;29(1):213-221
pubmed: 31595451
Aust N Z J Public Health. 2000 Feb;24(1):29-34
pubmed: 10777975
Br J Clin Psychol. 2007 Mar;46(Pt 1):1-18
pubmed: 17472198
Lung Cancer. 1995 Jun;12(3):199-220
pubmed: 7655830
J Parkinsons Dis. 2011;1(2):185-96
pubmed: 23934920
Arthritis Care Res (Hoboken). 2014 Mar;66(3):481-8
pubmed: 23983000
Aust N Z J Public Health. 2002 Aug;26(4):343-5
pubmed: 12233955
Appl Psychol Meas. 2017 May;41(3):178-194
pubmed: 29881087
Res Nurs Health. 2017 Aug;40(4):378-386
pubmed: 28732149
Psychol Med. 2002 Jul;32(5):889-902
pubmed: 12171383
Physiotherapy. 2011 Mar;97(1):83-9
pubmed: 21295243
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Res Social Adm Pharm. 2018 Nov;14(11):1080-1084
pubmed: 29366669
Lung. 2014 Oct;192(5):749-58
pubmed: 24907066
Lung Cancer. 2017 Nov;113:140-151
pubmed: 29110842
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Qual Life Res. 2014 Oct;23(8):2195-203
pubmed: 24648191
Health Expect. 2018 Apr;21(2):457-465
pubmed: 29130585